UNSPSC 51342308: Valganciclovir

This classification denotes a purine antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCU97FKN3R. European Medicines Agency schedules Valganciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00007MIG. Valganciclovir generally arises in the molecular formula C14H22N6O5.

UNSPSC 51342308 Valganciclovir (Commodity) shows minimal alignment with recent state and local procurement activity. The code nominally identifies a single antiviral pharmaceutical product, yet the four recent opportunities posted under this classification span naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing alliance. None of these solicitations explicitly reference valganciclovir or antiviral medications as a line item. The geographic and issuing-body distribution across these opportunities—Seminole County, Florida; Texas Health and Human Services Commission; City of Tampa; and the Minnesota Multistate Cooperative Purchasing Alliance (serving Minnesota and Oregon)—reflects a mix of county health departments, state agencies, municipal fire departments, and cooperative purchasing consortia rather than a coherent demand signal around the nominal commodity code.

The mismatch suggests either a tagging error within the procurement systems or that valganciclovir procurement, if occurring at the state and local level, is negligible enough that it does not generate standalone solicitation activity distinct from broader pharmaceutical or medical-supply categories. The recent opportunities indicate that state and local governments acquire specialty pharmaceuticals, emergency medical supplies, and OTC products through tiered approaches—direct county procurement (Seminole County IFB), state-level RFIs and RFPs (Texas HHS, MMCAP RFP), and small-local-business sheltered procurements (City of Tampa SLBE set-aside)—but none articulate valganciclovir as a procurement driver. Business development professionals should treat this code as inactive for current pursuit and monitor whether future opportunities correctly recategorize pharmaceutical procurement to more granular or therapeutically aligned codes.